Basic Information


GTO ID GTC0178
Trial ID NCT01875237
Disease Leukemia | Myeloma | Myeloproliferative Disease
Altered gene iCasp9
Therapeutic/Target gene Therapeutic gene
TherapyGene transfer
Treatment AP1903
Co-treatment Melphalan|Alemtuzumab|Tacrolimus|Mini Methotrexate|Filgrastim|AP1903|Methylprednisolone|Questionnaire
PhasePhase1|Phase2
Recruitment statusTerminated
TitleA Phase 1/2 Trial Evaluating Treatment of Emergent Graft Versus Host Disease (GvHD) With AP1903 After Planned Donor Infusions (DLIs) of T-cells Genetically Modified With the iCasp9 Suicide Gene in Patients With Hematologic Malignancies
Year2013
CountryUnited States
Company sponsorM.D. Anderson Cancer Center
Other ID(s)2012-0501|NCI-2013-01666
Vector information
Vectorretrovirus
Transgene/Inserted geneiCasp9 Suicide Gene

Clinical Result

Cohort1: stem cell transplant
Administration route infusion
Donor type autologous
Pts 0
Age Adult, Older_Adult
Lymph depletion Yes
Cohort2: DLI transplant
Administration route infusion
Dosage 3E6 cells/kg in 100 ml
Donor type autologous
Pts 1
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 1 participant had disease-free survivaI
Adverse reactions 1/1(All-cause mortality); 1/1(Infections and infestations)

Relationship Graph

Overview of Knowledge Graph